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Abstract
Background: Coumarin derivatives have been in world-wide use for rodent pest control for more
than 50 years. Due to their retarded action as inhibitors of blood coagulation by repression of the
vitamin K reductase (VKOR) activity, they are the rodenticides of choice against several species.
Resistance to these compounds has been reported for rodent populations from many countries
around the world and poses a considerable problem for efficacy of pest control.
Results: In the present study, we have sequenced the VKORC1 genes of more than 250 rats and
mice trapped in anticoagulant-exposed areas from four continents, and identified 18 novel and five
published missense mutations, as well as eight neutral sequence variants, in a total of 178 animals.
Mutagenesis in VKORC1 cDNA constructs and their recombinant expression revealed that these
mutations reduced VKOR activities as compared to the wild-type protein. However, the in vitro
enzyme assay used was not suited to convincingly demonstrate the warfarin resistance of all mutant
proteins
Conclusion: Our results corroborate the VKORC1 gene as the main target for spontaneous
mutations conferring warfarin resistance. The mechanism(s) of how mutations in the VKORC1 gene
mediate insensitivity to coumarins in vivo has still to be elucidated.
Background
Coumarin derivatives, e.g. warfarin, act as vitamin K-
antagonists and are in world-wide use as anticoagulants
for therapy and prophylaxis of thrombotic diseases in
humans, and as rodenticides for pest control. The physio-
logical target of coumarins is the endoplasmic enzyme
Published: 6 February 2009
BMC Genetics 2009, 10:4 doi:10.1186/1471-2156-10-4
Received: 3 April 2008
Accepted: 6 February 2009
This article is available from: http://www.biomedcentral.com/1471-2156/10/4
© 2009 Rost et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Genetics 2009, 10:4 http://www.biomedcentral.com/1471-2156/10/4
Page 2 of 9
(page number not for citation purposes)
vitamin K-epoxide reductase (VKOR) [1,2]. A key compo-
nent of the VKOR was recently identified and named
VKORC1 [3,4]. Mutations in VKORC1 have been shown
to cause two different hereditary phenotypes: warfarin-
resistance (OMIM #122700) and defective blood coagula-
tion owing to vitamin K-dependent coagulation factor
deficiency type 2 (VKCFD2; OMIM #607473) [3]. The
vitamin K-cycle provides vitamin K-hydroquinone, the
essential cofactor for the γ-glutamyl carboxylase catalysing
the post-translational modification of the vitamin K-
dependent proteins [5]. These proteins are involved in
blood coagulation (factor II, VII, IX, X, Protein S, C and Z),
cell cycle regulation (growth-arrest specific protein 6) and
bone metabolism (osteocalcin and matrix gla-protein)
[6,7]. Coumarins inhibit blood coagulation by suppress-
ing VKOR activity and consequently γ-carboxylation of
vitamin K-dependent proteins.
Warfarin is a first-generation anticoagulant and has been
used for pest control since the 1950's. Resistance to this
coumarin derivative was first observed in Rattus norvegicus
in the UK in 1958 [8] and led to the development of a
more potent "second-generation" of anticoagulants such
as difenacoum, bromadiolone and brodifacoum in the
1970's and 1980's. But soon after their introduction,
resistance to specific second generation compounds was
also observed in rodents [9-13].
In a previous publication, we have reported on a series of
mutations in the VKORC1 gene in warfarin resistant rat
and mouse populations from different areas in Europe
[14]. This report is an update of the mutation study pre-
senting novel mutations and common polymorphisms
found in rodents from anticoagulant-exposed areas in
Europe, South Africa, East Asia and both North and South
America. The different mutations were recombinantly
expressed in a human cell line and their VKOR activities
and inhibition by warfarin were studied.
Results and Discussion
More than 250 rats and mice from anticoagulant-exposed
areas in Europe, East Asia, South Africa and both North
and South America were screened for mutations in the
VKORC1 gene. Pre-screening by ARMS-PCR for the
Tyr139Cys mutation and subsequent sequence analysis of
all three exons and flanking intronic regions revealed a
panel of mutations and SNPs (single nucleotide polymor-
phisms) in the VKORC1 gene (Tables 1 and 2). Most of
these mutations have not been described before.
A recombinant expression system in HEK293 cells was
used to assay for the VKOR activities of the mutant pro-
teins in vitro and to study their sensitivity to warfarin (Fig.
1 and 2). Transfection efficiency was checked by Western
blotting using the anti-FLAG antibody M2 and was found
to be similar for all VKORC1 protein variants (data not
shown).
VKORC1 sequence variants
Some of the observed nucleotide variants do not result in
amino acid substitutions and are supposedly silent muta-
tions. Several of these SNPs (e.g. Ile107Ile, Thr137Thr)
were detected in rats from USA, Argentina, Thailand,
Indonesia and the Azores but not observed in European,
Korean or Japanese rats (Table 1). This may be explained
by independent population founder effects. The Ile82Ile
variant occurred at high frequency in rats from all conti-
nents except Africa. This SNP may, thus, be an ancestral
variant or may have arisen several times independently.
Of the variants which do cause amino acid substitutions,
isoleucine-90 was found to be substituted by leucine and
alanine-143 by valine in some rats from both North and
South America and/or Southeast Asia. However, in the
human VKORC1 protein these latter amino acids repre-
sent the wild-type (Fig. 3). Further, they are functionally
conservative amino acid substitutions and show similar or
even higher VKOR activities than the wild-type in vitro
(Fig. 1). Thus, these substitutions can be considered func-
tionally neutral variants. Isoleucine-141 was substituted
by valine in some rats from Indonesia. It reduces VKOR
activity to the half of the wild-type activity in vitro. In the
VKORC1 of other species, e.g. T. rubripes, G. gallus and A.
gambiae (Fig. 3) valine represents the wild-type at position
141. The effect of the Ile141Val mutation in combination
with the change from alanine-143 to valine which was
observed in one rat from Indonesia remains to be investi-
gated.
Other amino acid substitutions were shown to only have
a slight effect on VKOR activity in the in vitro assay. The
glutamate residue at position 37 was found to be substi-
tuted by glycine in 12 mice from Berlin, Germany. This
glutamate is not highly conserved, not even in other ver-
tebrates, e.g. the human VKORC1 has an arginine at this
position (Fig. 3). VKOR activity assays of the Gly37 vari-
ant revealed a basal VKOR activity of 75% compared to
the wild-type protein. The Gly37 variant is inhibited by
warfarin in a manner comparable to the wild-type murine
VKORC1 protein (Fig. 2). Thus, Gly37 rather seems to be
a polymorphism in the murine VKORC1 with only a
minor effect on protein function.
VKORC1 mutations
English rats showed the greatest diversity of mutations in
the VKORC1 gene. Three already described mutations
could be detected in rats trapped in different English
counties: the Tyr139Cys substitution was found in rats
from Gloucestershire, Norfolk and Lincolnshire, the
Tyr139Ser mutation in rats from Shropshire and theBMC Genetics 2009, 10:4 http://www.biomedcentral.com/1471-2156/10/4
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Leu128Gln substitution could be shown in rats from Lan-
cashire. All three mutations confer a moderately reduced
VKOR activity and are resistant to warfarin inhibition to a
variable degree (Fig. 2 and [14]). In two confirmed warfa-
rin-resistant rats from Nottinghamshire an Arg33Pro sub-
stitution was observed. VKOR activity of the Arg33Pro
variant was reduced to 42% of wild-type activity. A
Phe63Cys substitution was detected in rats from Cam-
bridge, including two rats with an additional hetero-
zygous point mutation leading to either an Ala26Thr or a
Tyr39Asn amino acid exchange. While Ala26Thr has –
similar to Ala26Ser – only a moderate effect on VKOR
activity with a reduction to approximately 56% of wild-
type activity, the Phe63Cys and the Tyr39Asn substitu-
tions reduce the VKOR activity to about 30% of normal.
Since both amino acids Phe63 and Tyr39 are highly con-
served in vertebrates and also in the mosquito, a substitu-
tion of these amino acids is expected to have an influence
on protein function.
VKOR activity measurements of the Glu67Lys variant
(observed in six rats from Japan) showed a reduced vita-
min K epoxide turnover of about 33% compared to the
wild-type protein. However, none of these novel muta-
tions seems to have an effect on warfarin sensitivity in
vitro.
The most drastic effect on VKOR activity was observed for
the Trp59Arg substitution. Only 16% residual VKOR
activity could be measured after recombinant expression
Table 1: VKORC1 mutations and polymorphisms found in Rattus norvegicus from different geographic areas.
Geographic area Amino acid substitutions No. of samples Silent mutations
England Cambridge/Essex Phe63Cys, Ala26Thr 1 Ile82Ile
Phe63Cys, Tyr39Asn 1 Ile82Ile
Phe63Cys 15 Ile82Ile
Norfolk Tyr139Cys 1 Ile82Ile
Tyr139Cys 1 --
Gloucestershire Tyr139Cys 1 --
Lincolnshire Tyr139Cys 2 Ile82Ile
Shropshire Tyr139Ser 2 --
Lancashire Leu128Gln 2 --
Nottinghamshire Arg33Pro 2 --
Hungary Békés Tyr139Cys 1 Ile82Ile
-- 2 Ile82Ile
Maglód Tyr139Cys 9 not investigated
Azores Terceira Ile90Leu, Val112Leu 2 Leu94Leu, Ile107Ile, Thr137Thr, Ala143Ala
Ile90Leu 1 Leu94Leu, Ile107Ile, Thr137Thr, Ala143Ala
Ile90Leu 1 Ile107Ile, Thr137Thr
-- 12 Ile82Ile
Korea Seoul Tyr139Phe 6 --
Tyr139Phe, Ala21Thr 1 --
-- 1 Ile82Ile
Indonesia -- 3 Ile82Ile
Ile90Leu 5 Ile107Ile, Thr137Thr
Ile90Leu, Ala143Val 1 Ser103Ser, Ile107Ile, Thr137Thr
Ile90Leu, Ile141Val, Ala143Val 1 Ser103Ser, Ile107Ile, Thr137Thr
Ile90Leu, Ile141Val 6 Ile107Ile, Thr137Thr
Thailand Ala143Val 2 Ser103Ser, Ile107Ile, Thr137Thr
Japan Glu67Lys 6 --
USA Santa Cruz Ile90Leu 3 Arg12Arg, Leu94Leu, Ile107Ile, Thr137Thr, Ala143Ala
Chicago Arg35Pro 6 --
Arg35Pro 8 Ile82Ile
-- 4 Ile82Ile
Argentina Buenos Aires Trp59Arg, Ile90Leu 7 Arg12Arg, Leu94Leu, Ile107Ile, Thr137Thr, Ala143Ala
-- 8 Ile82IleBMC Genetics 2009, 10:4 http://www.biomedcentral.com/1471-2156/10/4
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of this VKORC1 mutant. Therefore, warfarin resistance
could not be tested for in vitro. The Trp59Arg mutation
was found both in heterozygous and homozygous geno-
types in rats from Argentinean poultry farms. Anticoagu-
lants have been intensively used in these agricultural areas
for rodent pest control. In contrast, rats trapped on a waste
deposit in Buenos Aires showed no amino acid substitu-
tions in the VKORC1 protein. Given the low in vitro-activ-
ity of the Trp59Arg substitution, one could expect animals
homozygous for this mutation to suffer from a deficiency
of vitamin K-dependent coagulation factors with an
increased bleeding risk even without warfarin uptake. In
Table 2: VKORC1 mutations and polymorphisms found in Mus musculus from different geographic areas in Germany and from 
Terceira, Azores.
Geographic
area
Amino acid
substitutions
No. of samples Silent
mutations
Berlin Glu37Gly 12 --
Lower Saxony Glu37Gly 1 --
Westphalia Arg58Gly 13 --
Arg12Trp, Ala26Ser, Ala48Thr, Arg58Gly, Arg61Leu 7 Glu37Glu
Arg12Trp, Ala26Ser, Ala48Thr, Arg61Leu 2 Glu37Glu
Rhineland Leu128Ser 17 --
Tyr139Cys 1 --
Azores Tyr139Cys 1 --
Relative VKOR activities of different rat VKORC1 variants after recombinant expression in HEK293 cells Figure 1
Relative VKOR activities of different rat VKORC1 variants after recombinant expression in HEK293 cells. Light 
grey bars indicate basal VKOR activities of the variants in the absence of warfarin; dark grey bars show VKOR activities after 
addition of 60 μM warfarin. The specific activity of the recombinant rat wild-type enzyme (WT) was 1.0 ± 0.37 nmoles/mg pro-
tein × h and was set to 100% for comparison. Standard deviations are indicated by black error bars.BMC Genetics 2009, 10:4 http://www.biomedcentral.com/1471-2156/10/4
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theory, these rats could be rescued by a much higher vita-
min K intake as has been described for some warfarin
resistant laboratory strains [15-17]. Field investigations of
the relative fitness of warfarin-resistant rats on a farm in
Shropshire (UK) showed that when selection pressure
from anticoagulant use was removed, the frequency of the
warfarin resistance gene fell from 80 to 33% over 18
months [18].
Seven mice trapped in Münsterland, Germany, carried the
same 5 amino acid substitutions each (Table 2), thus pos-
ing the question which conferred warfarin resistance in
vivo, either independently or in combination. Recom-
binant VKOR activities of the variants Ala26Ser and
Ala48Thr – when studied separately – were determined at
67% and 118% of normal, respectively. While Ala26 is
conserved in most vertebrates, there is a serine at this posi-
tion in the fruitfly and a threonine in the mosquito
VKORC1 (Fig. 3). Similarly, Ala48 is only conserved in
higher vertebrates and is substituted by serine in chicken
or by arginine in the mosquito (Fig. 3).
Expression of the variants Arg12Trp, Arg58Gly and
Arg61Leu revealed a strong influence on vitamin K epox-
ide reduction compared to the wild-type protein. All three
substitutions reduced VKOR activity to 33%, 39% and
49% of the mouse wild-type, respectively. However, none
of these substitutions on their own, conferred a significant
warfarin resistance in the in vitro assay (Fig. 2). The
Arg58Gly substitution was also found as the only variant
– either heterozygous or homozygous – in a total of 13
mice from Germany. The same mutation was described
before in a warfarin-resistant patient from Norway (Table
3) [3]. This patient required a weekly dose of 220–250 mg
warfarin for an effective anticoagulation therapy (normal
dose: 10–60 mg per week). Although warfarin resistance
is clearly evident for this patient in vivo it could not be
demonstrated in vitro for the Arg58Gly variant nor for the
other mutations detected in mice, except for the
Tyr139Cys mutation found in wild mice from the Rhine-
land, Germany and from Terceira, Azores. This mutation
has previously been found in anticoagulant-resistant
breeding colonies derived from wild mouse populations
in England [3,14]. These findings suggests a wide distribu-
tion and some selective advantage for this resistance-
mediating mutation in mice.
In the in vitro assay used to measure VKOR activity, sur-
prisingly most mutations were rather sensitive to inhibi-
tion by warfarin. In the assay used, transfected cells are
lysed with relatively high concentrations of detergent
(0.5% CHAPS) and, thus, the hydrophobic membrane
environment that is required for VKOR activity [19] may
have been impaired. These results are, however, consistent
Relative VKOR activities of different mouse VKORC1 variants after recombinant expression in HEK293 cells Figure 2
Relative VKOR activities of different mouse VKORC1 variants after recombinant expression in HEK293 cells. 
The specific activity of the recombinant murine wild-type enzyme was 0.65 ± 0.15 nmoles/mg protein × h. This value was set to 
100% for comparison. For further details see legend to Figure 1.BMC Genetics 2009, 10:4 http://www.biomedcentral.com/1471-2156/10/4
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with earlier studies on VKOR activity in liver microsomal
preparations from Scottish [20,21] and Chicago [22] war-
farin-resistant strains of rats that have now been shown to
be homozygous for the Leu128Gln and Arg35Pro substi-
tutions, respectively, in VKORC1 [14]. Those studies used
intact liver microsomal preparations to determine the
kinetic parameters of VKOR activity and its sensitivity to
warfarin inhibition. In both resistant strains, the enzyme
parameters were found to be very similar to those of war-
farin-susceptible laboratory rats. There was evidence,
however, that warfarin was less tightly bound to the
microsomal preparations from resistant strains and inhi-
bition of VKOR was reversible [21,22]. Similar work on
hepatic microsomal preparations from a resistant mouse
strain – now known to carry a Leu128Ser substitution in
VKORC1 [14] – showed the same activity and warfarin
sensitivity of VKOR as in susceptible mice [23].
Alignment of VKORC1 proteins of different species Figure 3
Alignment of VKORC1 proteins of different species. Amino acid substitutions which could be detected in the examined 
rats and mice are highlighted by grey shading. Black boxes indicate the predicted transmembrane domains (according to the 
topology model of Tie et al., 2005 [30]). Blue shaded amino acid residues refer to the CXXC motif which is supposed to be the 
active site of the VKORC1 protein. The TYA motif which is highlighted in pink is the proposed warfarin binding site [25].BMC Genetics 2009, 10:4 http://www.biomedcentral.com/1471-2156/10/4
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So far, in vivo- and in vitro-data on warfarin resistance
match only for substitutions at amino acid position 139
of the VKORC1 protein. Tyr139Cys was identified in this
study in two rats from Hungary as well as in five wild-
caught English rats and was reported before in rats from
Germany (Münsterland), Denmark and from England
[14]. In this earlier report, rats were characterized as war-
farin-resistant by the blood clotting response test (BCR).
The mutation Tyr139Phe was found in six Korean rats in
this study, and had been detected before in French and
Belgian rats [14]. Warfarin has been extensively used and
supplied free of charge to the citizens in Korea since the
1950's. The Tyr139Ser substitution which could be
detected in two rats from Shropshire, England had been
described in a laboratory strain of rats derived from wild
animals trapped in the same area 30 years before [24]. In
the recombinant expression system, basal VKOR activities
of the Tyr139Cys, the Tyr139Phe and the Tyr139Ser vari-
ants, respectively, were lower than of the rat wild-type pro-
tein but in the presence of 60 μM warfarin a significantly
higher residual VKOR activity was retained (Fig. 1). There-
fore, rats bearing either of the Tyr139 mutations should
have an enormous selective advantage in warfarin-
exposed areas. We have speculated earlier that Tyr139 may
be part of the warfarin binding site of VKORC1 [25].
The synopsis of mutations in VKORC1 (Table 3) shows
that amino acid substitutions are observed all over the
gene with foci on positions 29 to 48 in exon 1, positions
58 to 67 in exon 2, and 120 to 143 in exon 3. The substi-
tutions Arg33Pro, Arg35Pro, Trp59Arg, Leu120Gln,
Leu128Gln, Leu128Ser, Tyr139Cys, Tyr139Phe and
Tyr139Ser have been associated with positive results from
in vivo resistance testing (by blood clotting response or no-
choice feeding tests) in rodents; the replacements
Val29Leu, Val45Ala, Arg58Gly, Val66Met and Leu128Arg
Table 3: Overview of mutations found in VKORC1 in rats, mice and humans.
Rattus norvegicus NCBI_ss# Mus musculus/
Mus domesticus
Homo
sapiens
Reference
Arg12Arg 107794658 -- -- this study
-- -- Arg12Trp -- this study
Ala21Thr 107794659 -- -- this study
Ala26Thr 107794660 Ala26Ser -- this study
-- -- -- Val29Leu [3]
Arg33Pro 107794661 -- -- [13]; this study
Arg35Pro 107794662 -- -- [14]; this study
-- -- Glu37Gly -- this study
Tyr39Asn 107794663 -- -- this study
-- -- -- Val45Ala [3]
-- -- Ala48Thr -- this study
Ser56Pro 107794664 -- -- this study
-- -- Arg58Gly Arg58Gly [3]; this study
Trp59Arg 107794665 -- -- this study
-- -- Arg61Leu -- this study
-- -- -- Val66Met [28]
Phe63Cys 107794666 -- -- this study
Glu67Lys 107794667 -- -- this study
Ile82Ile 107794668 -- -- this study
Ile90Leu 107794669 -- -- this study
Leu94Leu 107794670 -- -- this study
Ser103Ser 107794671 -- -- this study
Ile107Ile 107794672 -- -- this study
Val112Leu 107794673 -- -- this study
Leu120Gln 107794674 -- -- [14]
Leu128Gln 107794675 Leu128Ser Leu128Arg [3,14]; this study
Thr137Thr 107794676 -- -- this study
Tyr139Phe 107794677 -- -- [14,29]; this study
Tyr139Cys 107794678 Tyr139Cys -- [3,14]; this study
Tyr139Ser 107794679 Tyr139Ser -- [14]; this study
Ile141Val 107794680 -- -- this study
Ala143Ala 107794681 -- -- this study
Ala143Val 107794682 -- -- this study
Mutations in bold indicate where resistance was proven in rats or mice, or dosing problems in humans were reported. All sequence variants found 
in rats were submitted to dbSNP at NCBI http://www.ncbi.nlm.nih.gov/sites/entrez and are indicated by their distinct NCBI_ss# numbers.BMC Genetics 2009, 10:4 http://www.biomedcentral.com/1471-2156/10/4
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have been correlated with an increased coumarin require-
ment for maintaining normal clotting times in human
thrombophilic patients. These changes in the VKORC1
protein could, therefore, be associated with the in vivo
warfarin resistance phenotype. For amino acid substitu-
tions of Tyr139, this can be followed by the in vitro resist-
ance of recombinant VKORC1 activity to warfarin (Fig. 1).
For the remaining substitutions, their relation to in vivo
resistance remains to be demonstrated.
Conclusion
In conclusion, we have identified 18 novel amino acid
substitutions and five known mutations, as well as eight
silent sequence variants in the VKORC1 gene of wild rats
and mice trapped in anticoagulant-exposed areas on four
continents. Although not all of these rodents were classi-
fied as warfarin-resistant by BCR or laboratory feeding
tests, most of them had survived in an anticoagulant-
treated habitat. In a recombinant expression system,
VKOR activity was substantially reduced by most
VKORC1 variants compared to the wild-type proteins but
reduced sensitivity to warfarin inhibition could not be
demonstrated in this assay except for the Tyr139 variants.
In the Welsh-type resistant laboratory rat strain carrying
the Tyr139Ser substitution, low VKOR activity (25–50%
in comparison to the susceptible rats) was found to be
associated with an enhanced (> 10-fold) dietary vitamin K
requirement [17]. It is not known whether a similar die-
tary compensation would be possible in the wild. Further
studies are needed to establish the mechanism by which
mutations in the VKORC1 gene lead to warfarin resist-
ance.
Methods
Animals
Wild rats (Rattus norvegicus) were trapped in known or sus-
pected resistance areas in Hungary, England, Indonesia,
Korea, Japan, Thailand, South Africa, the USA, Argentina
and one island of the Azores. Rats from Chicago, Illinois
came from a breeding colony at Genesis Laboratories,
Colorado. The founder population of this breeding col-
ony had been acquired in July 2000 by live-trapping rats
in Chicago [26]. Three past GLP studies at Genesis Labo-
ratories have identified about half of the animals from the
same location in Chicago to be resistant to warfarin by
feeding tests [27].
Wild mice (Mus musculus) came from four areas of Ger-
many (Lower Saxony, Berlin, Westphalia and Rhineland)
and from the island of Terceira, Azores.
Samples were collected from 2005 through 2007, except
for the English rat samples from Gloucestershire, Lanca-
shire, Lincolnshire, Norfolk, Nottinghamshire and Shrop-
shire, which were from rats trapped in 1994 through 1996
and stored frozen.
DNA was extracted from different tissues using standard
procedures. The warfarin resistance status of the rodents
had been checked in a few cases using blood clotting
response [13] or feeding tests [27], but was unknown in
most cases.
All sampling was done under licence and authorization of
the regional rodent pest control authorities in accordance
with national legislation.
ARMS-PCR and sequence analysis
After DNA extraction, all samples were tested by an allele-
specific PCR (ARMS) for the presence of the Tyr139Cys
mutation which is the prevalent mutation in warfarin
resistant rats and mice from North-Western Europe [14].
Samples which were negative in the ARMS test or showed
an abnormal band pattern (divergent from the Tyr139Cys
band pattern) were sequenced for the three exons of the
VKORC1 gene on an automatic sequencer CEQ8000,
Beckman Coulter. Primer sequences are available on
request and conditions are as described by Pelz et al.,
2005 [14].
Cloning and mutagenesis
Rat and mouse VKORC1 cDNAs were cloned into the
pCEP4 vector (Invitrogen, Carlsbad, California) and a N-
terminal FLAG tag (M-DYKDDDDK) was added to the
construct for monitoring of the transfection efficiency by
Western blot analysis. Mutations were introduced into the
pCEP4-VKORC1 construct with the QuikChange muta-
genesis kit (Stratagene, Amsterdam, NL) according to the
manufacturer's instructions.
Expression and VKOR activity assay
For the recombinant expression of rat and mouse
VKORC1 variants HEK293-EBNA cells (Invitrogen, Karl-
sruhe, Germany) were used as described earlier [25]. The
VKOR enzymatic activity of the various VKORC1 proteins
was measured in whole-cell extracts before and after addi-
tion of different warfarin concentrations as described by
Rost et al., 2005 [25]. Aliquots of whole-cell protein
extracts were separated on 4–12% NuPAGE gels (Invitro-
gen, Karlsruhe, Germany) according to the manufacturer's
instructions and blotted onto nitrocellulose membranes
(Whatman Schleicher & Schuell, Dassel, Germany). Mon-
oclonal FLAG M2 antibody (Sigma-Aldrich) was used for
immuno-staining of the Western blots.
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